PALB2 and breast carcinoma: Zhou JJ et al. reported a significant difference in PALB2 pathogenic variants between patients aged ≤ 30 years and those > 30 years (p = 0.04) in an unselected breast cancer cohort in China (Zhou et al. 2020).